Wordt geladen...
IL-15 in the Combination Immunotherapy of Cancer
We completed clinical trials of rhIL-15 by bolus, subcutaneous, and continuous intravenous infusions (CIV). IL-15 administered by CIV at 2 mcg/kg/day yielded a 38-fold increase in 10- day number of circulating NK cells, a 358-fold increase in CD56(bright) NK cells and a 5.8-fold increase in CD8 T ce...
Bewaard in:
| Gepubliceerd in: | Front Immunol |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7248178/ https://ncbi.nlm.nih.gov/pubmed/32508818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00868 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|